Clinic
North Colorado Medical Center
North Colorado Medical Center was paid $21.39M by Medicaid between Jan 2018 and Dec 2024, across 205 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoNORTH COLORADO MEDICAL CENTER
GREELEY, CO 80631
GREELEY, CO 80631
33aNPI1720004450assigned 07/14/2006
33bProvider typeInfusion Therapy Clinic/Center
28Total paid$21.39M
24GClaims672,038
24DCodes billed205
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 89,719 | $2.88M | |
| 2019 | 88,671 | $2.46M | |
| 2020 | 83,133 | $2.20M | |
| 2021 | 126,514 | $3.52M | |
| 2022 | 116,856 | $3.88M | |
| 2023 | 99,793 | $3.65M | |
| 2024incomplete | 67,352 | $2.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 49,350 | 46,801 | $6.34M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 50,537 | 47,030 | $6.10M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.1% | 15,412 | 13,924 | $1.73M |
| 80053 | Comprehensive metabolic panel | 4.9% | 65,282 | 58,129 | $1.06M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.3% | 7,655 | 7,263 | $715K |
| 87631 | 2.5% | 7,726 | 7,187 | $535K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 2,354 | 2,158 | $519K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 1,276 | 1,176 | $378K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 1,708 | 1,582 | $304K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 1,513 | 1,448 | $301K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 5,083 | 4,870 | $255K |
| 80320 | 1.2% | 4,117 | 3,583 | $250K |
193 more codes
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 10,833 | $193K |
| G0378 | Hospital observation service, per hour | <1% | 2,110 | $142K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,723 | $141K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 3,109 | $141K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,206 | $130K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,239 | $114K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,484 | $111K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 61,362 | $108K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,273 | $105K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 483 | $97K |
| 80061 | Lipid panel | <1% | 7,795 | $97K |
| 82043 | <1% | 1,392 | $76K | |
| J3490 | Unclassified drugs | <1% | 43,614 | $72K |
| 84484 | <1% | 4,426 | $70K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,006 | $65K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,658 | $65K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 730 | $64K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 889 | $57K |
| 86140 | <1% | 2,865 | $52K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,153 | $52K |
| 87510 | <1% | 856 | $43K | |
| 87340 | <1% | 1,486 | $36K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 55 | $36K |
| 83605 | <1% | 1,760 | $35K | |
| 81001 | <1% | 16,392 | $34K | |
| 84439 | <1% | 3,060 | $32K | |
| 82728 | <1% | 1,426 | $31K | |
| 86762 | <1% | 776 | $29K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 146 | $29K |
| 87480 | <1% | 856 | $27K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 683 | $27K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 243 | $23K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 62 | $23K |
| 86803 | <1% | 1,464 | $23K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 1,456 | $22K |
| 87660 | <1% | 856 | $21K | |
| 83880 | <1% | 412 | $20K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 187 | $18K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $18K |
| 83540 | <1% | 1,406 | $15K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,756 | $15K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 1,399 | $15K |
| 85027 | <1% | 5,656 | $15K | |
| 83735 | <1% | 3,896 | $15K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 491 | $15K |
| 80076 | <1% | 605 | $14K | |
| 80074 | <1% | 527 | $14K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,911 | $13K |
| 84702 | <1% | 1,201 | $12K | |
| 85652 | <1% | 1,721 | $12K | |
| 86850 | <1% | 947 | $11K | |
| 82607 | <1% | 1,393 | $10K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 795 | $10K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 36 | $10K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,092 | $9K |
| A0425 | Ground mileage, per statute mile | <1% | 3,887 | $9K |
| 83690 | <1% | 11,619 | $8K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 473 | $8K |
| 84153 | <1% | 452 | $8K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 85 | $7K |
| 83550 | <1% | 1,068 | $7K | |
| 84403 | <1% | 588 | $7K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 113 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 97 | $7K |
| 83001 | <1% | 512 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 27 | $6K |
| 82670 | <1% | 359 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,047 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,381 | $5K |
| 84481 | <1% | 1,382 | $5K | |
| 80306 | <1% | 3,766 | $5K | |
| 86431 | <1% | 210 | $5K | |
| 85610 | <1% | 1,643 | $5K | |
| 84156 | <1% | 306 | $5K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $5K |
| 86900 | <1% | 969 | $4K | |
| 82247 | <1% | 492 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,648 | $4K |
| 86769 | <1% | 93 | $4K | |
| 81003 | <1% | 2,906 | $4K | |
| 84146 | <1% | 340 | $3K | |
| 86706 | <1% | 197 | $3K | |
| 82950 | <1% | 736 | $3K | |
| 85379 | <1% | 217 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,978 | $3K |
| 36591 | <1% | 1,596 | $2K | |
| 82746 | <1% | 161 | $2K | |
| 86703 | <1% | 395 | $2K | |
| 90715 | <1% | 24 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,743 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,180 | $2K |
| 77336 | <1% | 35 | $2K | |
| 86901 | <1% | 969 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,869 | $2K |
| 80050 | General health panel | <1% | 553 | $2K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 236 | $2K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 222 | $2K |
| 72141 | <1% | 14 | $2K | |
| 84703 | <1% | 4,487 | $2K | |
| 83970 | <1% | 71 | $2K | |
| 97165 | <1% | 15 | $1K | |
| 76801 | <1% | 14 | $1K | |
| 95819 | <1% | 15 | $1K | |
| 80329 | <1% | 33 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 24 | $1K |
| 84550 | <1% | 434 | $1K | |
| 84466 | <1% | 222 | $1K | |
| 82951 | <1% | 43 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 31 | $1K |
| 82150 | <1% | 38 | $988.92 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 53,874 | $896.74 |
| 36415 | Collection of venous blood by venipuncture | <1% | 955 | $844.51 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,097 | $742.16 |
| 84480 | <1% | 77 | $621.07 | |
| 83002 | <1% | 86 | $601.02 | |
| 82248 | <1% | 31 | $579.31 | |
| 84144 | <1% | 44 | $534.59 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,770 | $521.19 |
| 86704 | <1% | 32 | $495.12 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 24 | $415.55 |
| 83525 | <1% | 28 | $378.97 | |
| 82565 | <1% | 83 | $360.19 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,691 | $355.83 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,035 | $332.67 |
| 83615 | <1% | 100 | $297.54 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,502 | $285.37 |
| 81025 | <1% | 788 | $271.51 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 554 | $240.72 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,095 | $212.78 |
| 88312 | <1% | 483 | $209.55 | |
| 86038 | <1% | 23 | $198.88 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,124 | $195.30 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 69 | $193.20 |
| 82952 | <1% | 14 | $178.44 | |
| 85014 | <1% | 46 | $131.40 | |
| 84100 | <1% | 56 | $119.81 | |
| 74021 | <1% | 116 | $113.67 | |
| 85046 | <1% | 15 | $83.11 | |
| 82310 | <1% | 40 | $78.38 | |
| 85018 | <1% | 46 | $65.70 | |
| 82550 | <1% | 13 | $51.94 | |
| 82330 | <1% | 83 | $49.36 | |
| 82570 | <1% | 16 | $48.71 | |
| 84460 | <1% | 13 | $46.30 | |
| 85730 | <1% | 189 | $41.44 | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,071 | $39.41 |
| 84436 | <1% | 19 | $38.52 | |
| 82977 | <1% | 13 | $35.28 | |
| 82947 | <1% | 540 | $29.12 | |
| 82435 | <1% | 83 | $26.74 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 36 | $21.09 |
| 87088 | <1% | 204 | $18.90 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 914 | $17.67 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,333 | $14.18 |
| 84520 | <1% | 83 | $13.31 | |
| 84295 | <1% | 83 | $13.31 | |
| 84132 | <1% | 83 | $13.31 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,117 | $8.99 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,205 | $8.80 |
| A9270 | Non-covered item or service | <1% | 215 | $2.28 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 102 | $1.51 |
| 87186 | 0% | 13 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 31 | $0.00 |
| 72100 | 0% | 15 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 128 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 12 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 223 | $0.00 |
| 72125 | Computed tomography, cervical spine; without contrast material | 0% | 12 | $0.00 |
| 73562 | 0% | 12 | $0.00 | |
| 88313 | 0% | 14 | $0.00 | |
| 84145 | 0% | 29 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 30 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 14 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 14 | $0.00 |
| 74018 | 0% | 13 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 14 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 1,393 | $0.00 |
| 87807 | 0% | 318 | $0.00 | |
| A0120 | Non-emergency transportation: mini-bus, mountain area transports, or other transportation systems | 0% | 162 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 202 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 115 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 56 | $0.00 |
| 87077 | 0% | 14 | $0.00 | |
| 74022 | 0% | 46 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 12 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 26 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 82 | $0.00 |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | 0% | 100 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 58 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 63 | $0.00 |
| 72040 | 0% | 24 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 58 | $0.00 |
| 88300 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialQUALLS, ALLAN (CEO)
Parent organizationBANNER HEALTH